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contrast agent was also detectable in the thickened cutis of both
calves. Based on this, we also started 50 mg/day prednisolone; a
decision which would have been questionable only on the basis of
our clinical findings. After 3 months the tissue tautness had
improved markedly and eosinophils were normal (336 cells/mm3).
The first description of MRI changes in EF was made in 1989.2
Since then, sporadic publications of MRI features of EF have
appeared mainly in radiological journals.3–6 Histological exam-
ination of all tissue layers from skin to muscle remains the
golden standard for the diagnosis of EF, however, MRI may be
helpful to confirm fascial inflammation, either if biopsy is not
meaningful or not possible. However, only a prospective study
can determine sensitivity and specificity of MRI for this
question and its value for differentiating diseases with similar
clinical presentation, such as localised scleroderma, graft versus
host disease or eosinophilia–myalgia syndrome.
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IgM-rheumatoid factor and anti-
cyclic citrullinated peptide decrease
by 50% during intensive treatment in
early rheumatoid arthritis
Decreases in rheumatoid factor (IgM-RF) during antirheumatic
treatment are often reported,1–4 but the course of anti-cyclic
citrullinated peptide (anti-CCP) is less conclusive, with some
studies showing decrease,2 5 6 but others finding no change.4 7 8
As anti-CCP antibodies are very specific as a marker for
rheumatoid arthritis (RA), decreases in anti-CCP levels on
therapy may have prognostic relevance and guide further
treatment decisions in patients with early RA.
A total of 21 patients with active, early RA were treated for
40 weeks with intensive conventional disease-modifying anti-
rheumatic drug (DMARD) therapy, comprising hydroxychlor-
oquine, sulfasalazine, methotrexate and tapered high-dose
prednisolone (enhanced ‘‘COBRA’’ (Combinatietherapie Bij
Reumatoide Artritis trial) schedule, fig 1). On non-response at
8 weeks, methotrexate (MTX)was intensified to 25 mg/week;
on non-response at 21 weeks, infliximab was offered to patients
on high-dose MTX and MTX was intensified in the remainder.
Serum was available for 18 out of 21 patients.
IgM-RF and anti-CCP were measured and analysed at
baseline and weeks 4, 8, 14, 21, 28, 32, 36 and 40. IgM-RF
was measured by an in-house ELISA (positive at .30 IU/ml)
and anti-CCP was measured using the anti-CCP2 ELISA
(positive at .5 AU/ml). The Wilcoxon signed rank test was
used to determine whether IgM-RF and anti-CCP at the
different time points differed significantly from baseline.
The mean age of the 18 participants was 52 years (range:
29–76); 72% were women and their mean disease duration was
3 months. At baseline, 5 out of 18 patients were IgM-RF
negative and 4 out of 18 were anti-CCP negative, resulting in
available data of 13 patients for the IgM-RF analysis and 14
patients for the anti-CCP analysis. As previously reported, 90%
of patients achieved 28-joint Disease Activity Score (DAS28)
remission.9
IgM-RF values decreased immediately by mean 58% in the
first 8 weeks during prednisolone treatment and by 63% after
40 weeks (p,0.05, table 1). Of 13 patients, 8 received MTX
intensification at 8 weeks and subsequently 4 received anti-TNF
at 21 weeks; 77% of patients experienced a >50% reduction in
IgM-RF after 40 weeks.
Similarly, anti-CCP antibody levels decreased significantly by
46% in the first 8 weeks and by 48% after 40 weeks (p,0.05)
(fig 1). For two patients, anti-CCP antibody levels increased
although RF decreased and they both achieved DAS28 remis-
sion. Of 14 patients, 9 received MTX intensification at 8 weeks
and subsequently 5 received anti-TNF at 21 weeks. After
40 weeks of controlled treatment, 86% of patients experienced
a >50% reduction in anti-CCP antibodies.
At 8 weeks, 6 out of 13 patients who were IgM-RF positive
turned IgM-RF negative; at 40 weeks, 5 remained IgM-RF
negative and 1 turned positive again. In contrast only 1 out of
14 patients who were anti-CCP positive turned negative at
21 weeks.
Table 1 28-Joint Disease Activity Score (DAS28), IgM-rheumatoid factor (RF) and anti-cyclic citrullinated protein (CCP) over 40 weeks of intensive
treatment for all 18 patients
Baseline 8 weeks 21 weeks 40 weeks
DAS28 5.2 (0.9) 5.2 (3.9–7.3) 2.3 (1.3) 2.4 (0.5–4.1)* 2.2 (1.4) 2.0 (0–5.2)* 2.2 (1.4) 1.4 (0–3.6)*
IgM-RF (U/ml) 190 (150) 49 (5–634) 52 (101) 24 (4–443)* 44 (79) 15 (3–340)* 44 (79) 15 (7–529)*
Anti-CCP (U/ml) 205 (227) 141 (0–850) 112 (137) 39 (0–454)* 93 (117) 35 (0–360)* 93 (117) 30 (0–1000)*
Values are mean (SD) or median (range).
*Significantly different from baseline (p,0.05) calculated using the Wilcoxon signed rank test.
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Rapid decreases in IgM-RF have also been documented in the
original COBRA trial10 and other studies1–4 11 12 but to our
knowledge such profound decreases of anti-CCP during treatment
of patients with early RA have not been described before.
As anti-CCP antibodies may have a pathogenic role in the
development of RA, including anti-CCP levels in tight control
strategies might increase the efficacy of such strategies in
preventing damage and disability. Unfortunately, our study was
too small and not designed to explore the relationship between
change in disease activity and a fall in anti-CCP antibodies and RF.
This study strengthens the suggestion that intensive conven-
tional treatment including initial high-dose prednisolone
according to the COBRA schedule, and infliximab add-on
where necessary, can lead to new levels of disease control in
early RA.
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Figure 1 Top: percentage change of anti-cyclic citrullinated peptide
(CCP) from baseline for all patients who were anti-CCP positive; the thick
light grey line represents the cp61523 mean percentage decrease of anti-
CCP for all patients who were anti-CCP positive. Bottom: all patients
received the original ‘‘COBRA’’ (Combinatietherapie Bij Reumatoide
Artritis trial) schedule (black), intensified by the addition of
hydroxychloroquine and methotrexate 10 mg instead of 7.5 mg and
continuation of low-dose prednisolone instead of tapering after 28 weeks
(dark grey). Decisions to intensify methotrexate and to start infliximab
infusions (light grey) were based on monitoring results.
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